HOOK News and Press, HOOKIPA Pharma Inc. From 12/21/23

2023-12-21 08:50:38 ET DENVER, Colo., Dec 21, 2023 ( www.247marketnews.com )- HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported, this morning, that Gilead Sciences, Inc. (NASDAQ: GILD) purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of...

Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per share Following the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock Equity investment is to advance the Gilead-partner...

2023-11-20 10:17:26 ET Whether you’re looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week with Thursday’s Thanksgivin...

Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (‘Gilead’), to be evaluated as a potential curative regimen for human immunodeficiency virus (HIV) Phase 1 trial to commence in the first half of 2024 Nature Partner Jo...

2023-11-09 07:08:31 ET More on HOOKIPA Pharma Seeking Alpha’s Quant Rating on HOOKIPA Pharma Historical earnings data for HOOKIPA Pharma Financial information for HOOKIPA Pharma For further details see: HOOKIPA Pharma GAAP EPS of -$0.17 beats by $0...

Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1 st -line setting for advanced HPV16+ head and neck cancer; data reinforce strong objective response rate and disease control rate reported in Q2 2023; randomized trial ...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

HOOKIPA Pharma Inc. (HOOK) is expected to report $-0.23 for Q3 2023

HB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+ head and neck cancer T cell responses were high quality, durable and suggest an association with clinical benefit based on disease contr...

NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial r...